BIO-Europe 2024
Biomica will be attending Bio Europe conference, and we’re looking forward to connecting with industry leaders and innovators. Our CEO, Dr. Elran Haber, and VP of Business Development, Mel Larrosa, will be available for meetings.
Biomica will be attending Bio Europe conference, and we’re looking forward to connecting with industry leaders and innovators. Our CEO, Dr. Elran Haber, and VP of Business Development, Mel Larrosa, will be available for meetings.
Dr. Elran Haber, CEO of Biomica, will be participating as a panelist at the 9th Microbiome Movement – Drug Development Summit. On July 12th at 9:30 am ET, Dr. Haber will engage in the panel discussion “Defining Innovative Clinical Strategies Conserving Spend.” This discussion will explore adaptive trial methodologies, strategic partnerships, and criteria for attracting […]
Preliminary Phase 1 results show promising trends for BMC128 in combination with nivolumab in refractory cancer patients. Data will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting REHOVOT, Israel, May 23, 2024. Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: […]
Biomica will present results from pre-clinical studies in its irritable bowel syndrome (IBS) program at the Digestive Disease Week (DDW) 2024 Annual Meeting. The conference is being held in Washington, D.C., May 18-21, 2024.
Biomica will present results from pre-clinical studies in its irritable bowel syndrome (IBS) program at the Digestive Disease Week (DDW) 2024 Annual Meeting. The conference is being held in Washington, D.C., May 18-21, 2024.
Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson’s. But the treatments for these and other debilitating conditions may be far closer to home than many realise.